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BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib are currently the standard treatment for
metastatic melanoma with BRAF V600 mutations. However, given the rarity of noncutaneous melanoma, including
acral and mucosal subtypes, the efficacy of BRAF inhibitors for this subset of patients has not been extensively
investigated. Acquired resistance generally appears 6 to 8 months after treatment with a BRAF inhibitor, and the
mechanism of resistance is not well established. METHODS: We examined treatment outcomes for patients
diagnosed with metastatic melanoma and treated with BRAF inhibitors at Samsung Medical Center between April
2013 and December 2015. We analyzed genomic alterations in selected patients using targeted sequencing.
RESULTS: Twenty-seven patients with a median age of 49 years (range 23-82 years) with metastatic melanoma and
treated with a BRAF inhibitor were identified. Of these patients, 19 (70.3%) had noncutaneous melanoma,
including acral and mucosal melanoma. All patients had BRAFV600E mutations. The median progression-free
survival of all patients was 9.2 months (95% confidence interval, 1.6-16.7), and the objective response rate was
78.9% in the mucosal/acral melanoma group and 75.0% in the cutaneous melanoma group. Three (11.1%)
patients achieved complete response, and 19 (70.4%) showed a partial response. Targeted sequencing in five
patients demonstrated NF1 mutations in three patients who did not respond to BRAF inhibitors. CONCLUSION:
BRAF inhibitors were an effective therapeutic option for Korean patients with metastatic melanoma harboring a
BRAF V600 mutation regardless of melanoma subtype (acral/mucosa versus cutaneous).
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Melanoma is a malignant neoplasm of melanocytes and can be
further subtyped as cutaneous (with or without chronic
sun-induced damage) and noncutaneous (e.g., acral and mucosal
melanoma) [1]. Noncutaneous melanomas are generally unrelated
to sun exposure and occur less frequently than cutaneous
melanomas in the United States [2]. In stark contrast to Caucasian
populations, however, noncutaneous melanomas are the major
subtype of malignant melanomas among Asians [3–5]. Noncuta-
neous and cutaneous melanomas are distinct in their genetic
alterations. For example, BRAF mutations commonly occur in
cutaneous melanomas but are relatively uncommon in acral/
mucosal melanomas [1,6,7].
BRAF mutations are discovered in approximately 50% of patients
with malignant melanoma, and the BRAF V600E mutation is the
most common (~80% of cases) [8,9]. The US Food and Drug
Administration has approved single agents with vemurafenib,
dabrafenib, and trametinib and the combination of dabrafenib and
trametinib, vemurafenib, and cobimetinib in patients with unresect-
able or metastatic melanoma with a BRAFmutation. In a clinical trial,
vemurafenib significantly improved survival compared with dacarba-
zine; the median overall survival was 13.6 months and 9.7 months for
the vemurafenib and dacarbazine groups, respectively, and the
median progression-free survival (PFS) was 6.9 months and 1.6
months [10]. The alternative treatment for metastatic melanoma
involves combined treatment of dabrafenib, a BRAF inhibitor, and
trametinib, an MEK inhibitor. Combining dabrafenib with trame-
tinib increased median PFS to 11.4 months and objective response
rate (ORR) to 64% [11].
Ultimately, however, the majority of patients develop resistance to
BRAF inhibitors, and recent studies have analyzed resistance
mechanisms [12–14]. Numerous genetic and nongenetic alterations
have been revealed, such as NRAS mutations [15], BRAF
amplification, [16] MEK1/2 mutations [17], and overexpression of
COT or EGFR [18,19]. These genetic alterations are related to the
mitogen-activated protein kinase pathway, which could drive
melanoma progression [12,20], but driver mutations for resistance
have not been well characterized.
Because most efficacy and tolerability data of BRAF inhibitors have
been established in cutaneous, non-Asian melanoma patients, we
undertook this study to analyze the efficacy of BRAF inhibitors in
Asian metastatic melanoma patients, where acral/mucosal melanoma
subtypes are the most common. We further investigated genomic
alterations in patients with BRAF-mutant melanoma using targeted
sequencing to identify potential genomic markers associated with
treatment response.
Material and Methods
Patients
This was a retrospective study of patients diagnosed with metastatic
melanoma and treated with BRAF inhibitors at Samsung Medical
Center between April 2013 and December 2015. Informed consent
was obtained from all patients. We reviewed the medical records of all
patients for clinical parameters, including sex, age, performance
status, primary melanoma site, metastatic sites, serum lactate
dehydrogenase level, BRAF mutation test results, and previous
treatments. The institutional review board of Samsung Medical
Center, Seoul, Korea, approved this study.Response Evaluation
Response evaluation was assessed every 2 months using thoracic
and abdominopelvic computed tomographic (CT) scans. CT scans
were subsequently used to assess tumor response. If there was
headache or neurologic symptoms, brain magnetic resonance imaging
was performed. Some patients (n = 2) were evaluated with
whole-body magnetic resonance imaging. All images were collectively
reanalyzed by radiologists, and tumor response was classified
according to Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1 [21] as complete response, partial response,
stable disease, or progressive disease in comparison with images
obtained just before beginning dabrafenib with trametinib or
vemurafenib therapy.
Statistical Analysis
PFS was defined as the time from the initial BRAF inhibitor
treatment date to the date of progression or date the patient was last
seen. The duration of response was defined as the time from the
documented date of tumor response to the date of progression. The
date of tumor response was defined as the first date that partial or
complete response is objectively documented, which was confirmed
by subsequent CT scan. The Kaplan-Meier method was used to
estimate PFS. Difference in survival was analyzed with the log-rank
test. Data were analyzed using SPSS 22.0 software (SPSS Inc.,
Chicago, IL).
Tumor Samples
Five patients underwent biopsies from metastatic sites at BRAF
inhibitor treatment baseline. Specimens were kept in reserve as
formalin-fixed, paraffin-embedded in accordance with institutional
standard operating procedures, and tumor cell content was more than
70% in all tumor foci.
Targeted Exome Sequencing
Genomic DNA was extracted, and a SureSelect customized kit
(Agilent Technologies, Santa Clara, CA) was used for capturing 381
cancer-related genes covering all exons in each gene [22,23]. Illumina
HiSeq 2500 was used for sequencing with 100-bp paired-end reads.
The sequencing reads were aligned to the human genome reference
sequence (hg19) using BWA-mem (v0.7.5), SAMTOOLS (v0.1.18),
Picard (v1.93), and GATK (v3.1.1) for sorting SAM/BAM files,
duplicate marking, and local realignment, respectively. Local
realignment and base recalibration were carried out based on
dbSNP137, Mills indels, HapMap, and Omni. SNVs and InDels
were identified using Mutect (v1.1.4) and Pindel (v0.2.4),
respectively. ANNOVAR was used to annotate the detected variants.
Only variants with a greater than 1% allele frequency were included
in the results. Copy number variations were calculated for targeted
sequencing regions by dividing read-depth per exon by the normal
reads per exon using an in-house reference.
Results
Patients
Twenty-seven patients with a median age of 49 years (range 23-82)
were treated with BRAF inhibitors. Eleven patients received
dabrafenib with trametinib, and 16 were treated with vemurafenib.
Patients received 150 mg of dabrafenib twice daily and 2 mg of
trametinib once daily or 960 mg of vemurafenib every 12 hours.
Table 1 shows the baseline characteristics of all patients. According to
Table 1. Baseline Characteristics
Total
(N = 27)
Dabrafenib
with
Trametinib
(n = 11)
Vemurafenib
(n = 16)
Sex
Male 12 (44.4%) 7 (63.6%) 5 (31.3%)
Female 15 (55.6%) 4 (36.4%) 11 (68.8%)
Median age (range), years 49 (23-82) 60 (39-82) 49 (23-65)
ECOG performance status
0-1 25 (92.6%) 11 (100%) 14 (87.5%)
2-3 2 (3.7%) 0 2 (12.6%)
Subtype of melanoma
Acral 10 (37.0%) 5 (45.5%) 5 (31.3%)
Mucosal 9 (33.3%) 1 (9.1%) 8 (50.0%)
Cutaneous 8 (29.6%) 5 (45.5%) 3 (18.8%)
Extent of disease at baseline
M1a 5 (18.5%) 4 (36.4%) 1 (6.3%)
M1b 1 (3.7%) 0 1 (6.3%)
M1c 21 (77.8%) 7 (63.6%) 14 (87.5%)
LDH higher than upper limit of
normal at baseline
12 (44.4%) 3 (27.3%) 9 (56.3%)
Visceral disease at baseline 21 (77.8%) 7 (63.6%) 14 (87.5%)
Number of disease site at baseline
Fewer than 3 9 (33.3%) 3 (27.3%) 6 (37.5%)
3 or more 18 (66.7%) 8 (72.7%) 10 (62.5%)
History of brain metastasis 7 (25.9%) 2 (18.2%) 5 (31.3%)
Current site of metastasis
Lung 12 (21.1%) 1 (9.1%) 11 (68.8%)
Distant LN 19 (70.4%) 6 (54.5%) 13 (8.1%)
Liver 13 (48.1%) 4 (36.4%) 9 (56.3%)
Bone 6 (22.2%) 1 (9.1%) 5 (31.2%)
Peritoneal seeding 4 (14.8%) 2 (18.2%) 2 (12.6%)
Previous adjuvant treatment
Immunotherapy 10 (37.0%) 4 (36.4%) 6 (37.5%)
Radiotherapy 8 (29.6%) 3 (27.3%) 5 (31.3%)
Chemotherapy 0 0 0
Previous systemic treatment for
metastatic melanoma
Immunotherapy 7 (11.1%) 3 (27.3%) 4 (25.0%)
Chemotherapy 5 (18.5%) 2 (18.2%) 3 (18.8%)
Biologic agent 6 (22.2%) 4 (36.4%) 2 (12.5%)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; LN, lymph node.
Table 2. Treatment Outcomes According to Types
Total
(N = 27)
Noncutaneous
(Acral/Mucosal)
(n = 19)
Cutaneous
(n = 8)
PFS, mo
Median 9.2 7.3 17.5
(95% CI) (1.6-16.7) (3.0-11.6) (0.-34.9)
Best response, n (%)
Complete response 3 (11.1) 2 (10.5) 1 (12.5)
Partial response 19 (70.4) 13 (68.4) 5 (62.5)
Stable disease 5 (18.5) 3 (15.8) 2 (25.0)
Progressive disease 1 (3.7) 1 (5.3) 0
Complete or partial response
No. of patients (%) 22 (81.5) 15 (78.9) 6 (75.0)
(95% CI) (57.2-100) (53.1-100) (44.9-100)
Duration of response, mo
Median 6.6 4.5 11.8
(95% CI) (3.4-9.8) (0.7-8.3) (5.8-17.7)
Range 0-26.0 0-26.0
2.1-25.4
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cutaneous melanoma, 10 (37.0%) with acral melanoma and nine
(33.3%) with mucosal melanoma. All patients tested positive for the
BRAF V600E mutation. The majority of patients had visceral
metastasis; common sites included the liver (48.1%) and lung
(21.1%). Seven (25.9%) patients had a history of brain metastasis.
Among the patients who underwent surgery, 10 (37.7%) were treated
with the adjuvant immunotherapy of interferon-α (Table 1).
Response to Treatment
Treatment outcomes are shown in Table 2 and Figure 1. The
median follow-up for all patients was 32.1 months [95% confidence
interval (CI), 24.9-39.1]. The median PFS for patients with
noncutaneous melanoma following treatment with BRAF inhibitors
was 7.3 months (95% CI, 3.0-11.6), whereas the median PFS for
cutaneous melanoma was 17.5 months (95% CI, 0.1-34.9). At 6
months posttreatment, the PFS rate was 50.2% (95% CI, 27.1-73.3)
in the noncutaneous melanoma group and 72.9% (95% CI,
40.56-100) in the cutaneous melanoma group. The PFS was not
significantly different between patients with noncutaneous and
cutaneous melanoma (P = .429; Figure 1B). ORR for patients with
noncutaneous melanoma was 78.9% (95% CI, 53.1-100) compared
with 87.5% for cutaneous melanoma. The median duration ofresponse was 4.5 months in the noncutaneous melanoma group and
11.8 months for the cutaneous melanoma group.
According to treatment regimen that patients received, dabrafenib
with trametinib showed significantly better PFS than treatment of
vemurafenib (median PFS, not achieved versus 4.7 months, P = .001;
Figure 1C). ORR was similar between two treatment regimen, 81.8%
for dabrafenib with trametinib and 81.3% for vemurafenib, respec-
tively. Figure 2 demonstrated best response from baseline by RECIST.
Toxicity
The most frequent side effects were pyrexia (36.4%) in patients
treated with dabrafenib and trametinib and a skin rash (62.5%) in
patients treated with vemurafenib. Dose interruption occurred in two
patients treated with dabrafenib and trametinib; one patient stopped
treatment because of grade 3 decreased cardiac ejection fraction and
grade 2 cardiac failure, and the other patient delayed treatment because
of grade 3 neutropenia. Among the patients treated with vemurafenib,
one received a reduced dose because of a grade 3 skin rash, but the dose
was elevated after the rash subsided. Known MEK inhibitor-associated
toxicities such as leg edema, hypertension, and decreased cardiac
ejection fraction were observed, but a dose-limiting event was rare.
Other adverse effects were rare, and most patients tolerated treatment.
No grade 4 adverse events were reported. (See Table 3).
Targeted Sequencing
Figure 3 shows the genetic heterogeneity among the five patients at
baseline biopsy. Patients (Pats) 02 and 03 received vemurafenib, and
Pats 01, 04, and 05 were treated with dabrafenib and trametinib.
Pat01 had short-lived stable disease (duration of response: 2.1
months); primary resistance was suspected. IKZF1, ELMO1, and
CDKN1B mutations were identified in Pat01. Patients with an NF1
mutation (Pats 01, 02, and 03) also demonstrated shorter duration of
response than patients without an NF1 mutation (Pats 04 and 05).
MAP2K2 mutation co-occurred with MYC and TMPRSS2
alterations in Pats 04 and 05, but the clinical significance was
uncertain. EGFR and PTEN mutations were identified in Pat 02,
who had a relative short PR of 7.1 months.
Discussion
BRAF inhibitors have become a standard therapy for patients with
metastatic melanoma and BRAF V600 mutation on the basis of
Figure 1. Kaplan-Meier survival curves by PFS. (A) PFS in all patients (N = 27). (B) PFS with noncutaneous melanoma and cutaneous
melanoma.
560 BRAF inhibitors in noncutaneous melanoma Kim et al. Translational Oncology Vol. 9, No. 6, 2016recent multicenter, randomized trials [24,25]. Most melanoma
patients in Caucasian populations have cutaneous melanoma, but
more than half of Asian melanoma patients have noncutaneous
melanoma. In the United States, noncutaneous melanomas comprise
less than 10% of melanoma cases [2] compared with 72% of Chinese
patients [26]. Among Koreans, 75.8% of melanoma cases are
noncutaneous melanoma [27]. According to ethnic differences in
primary melanoma sites, the results of recent randomized trials with
BRAF inhibitors do not fully warrant their use in treating
noncutaneous melanoma. Our findings suggest that BRAF inhibitors
might be a feasible and tolerable treatment option for Asian patients
with noncutaneous metastatic melanoma who test positive for a
BRAF V600 mutation.
We found that 19 of 27 Korean patients (70.3%) had
noncutaneous melanoma with the BRAF V600E mutation. In astudy by Robert et al. [11], combination therapy with dabrafenib and
trametinib increased median PFS and ORR compared with
vemurafenib (median PFS 11.4 months vs 7.3 month; ORR 64%
vs 51%). We also found similar efficacy in current study: a median
PFS in vemurafenib group was 4.7 months and not achieved in
dabrafenib with trametinib group, and ORR was 75% in vemurafenib
group and 81.5% in dabrafenib with trametinib group. Accordingly,
the results presented here are comparable to the results of previous
randomized trials with BRAF inhibitors in melanoma patients.
Furthermore, PFS was not significantly different between patients
with noncutaneous and cutaneous melanoma (P = .429; Figure 1B),
suggesting that the efficacy of BRAF inhibitors is not profoundly
influenced by site of origin or ethnicity.
In terms of median duration of response, phase 3 trial of dabrafenib
with trametinib and vemurafenib showed 13.8 months and 7.5
Table 3. Toxicity Profile
Toxicity Dabrafenib with Trametinib Vemurafenib
(n = 11) (n = 16)
Grade 3 or 4 All Grades Grade 3 or 4 All Grades
No. of patients (%)
Pyrexia 0 4 (36.4) 0 0
Anorexia 0 2 (18.2) 1 (6.3) 6 (37.5)
Nausea 0 2 (18.2) 0 3 (26.4)
Vomiting 0 1 (9.1) 0 0
Diarrhea 0 3 (27.3) 0 2 (12.5)
Constipation 0 1 (9.1) 0 2 (12.5)
Fatigue 0 5 (45.4) 0 4 (25.0)
Headache 0 1 (9.1) 0 1 (6.3)
Skin rash 0 3 (27.3) 1 (6.3) 10 (62.5)
Hand foot syndrome 0 0 0 4 (25.0)
Decreased ejection fraction 1 (9.1) 1 (9.1) 0 0
Cardiac failure 0 1 (9.1) 0 0
Leg edema 0 2 (18.2) 0 1 (6.3)
Hypertension 0 1 (9.1) 0 0
Neutropenia 1 (9.1) 2 (18.2) 0 0
Dry skin 0 1 (6.3)
Acne 0 2
Mucositis 0 1 (6.3)
Pruritus 0 1 (6.3)
Alopecia 0 5
Myalgia 0 3
Cough 0 1 (6.3)
Photosensitivity 1 (6.3) 1 (6.3)
Hyperpigmentation 0 2 (12.5)
Sensory neuropathy 0 3 (26.4)
Pain 0 2 (12.5)
Nail changes 0 1 (6.3)
Insomnia 0 1 (6.3)
No grade 4 events.
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response between two treatment groupswasmore prominent; treatment
with vemurafenib demonstrated inferior outcome in our study (16.7
months in dabrafenib with trametinib vs 3.3 months in vemurafenib
group). One of the explanatory reasons was selection bias; the patients in
the vemurafenib group had worse performance status, more non-
cutaneous melanoma, and more metastatic and advanced disease (high
lactate dehydrogenase, visceral disease, brain metastasis; Table 1).
Previous studies have indicated that patients treated with BRAF
inhibitors become resistant to drugs 6 to 7 months after the initiation
of therapy [24,28,29]. In our study, the 16 patients treated with
vemurafenib showed disease progression, with a median PFS of 4.7
months (95% CI, 2.5-6.8). In contrast, only 3 among 11 patients
who received dabrafenib and trametinib showed disease progression.
Thus, there was a significant difference in PFS between the
vemurafenib-treated group and the dabrafenib with trametinib–
treated group (i.e., median PFS 4.7 months versus not achieved; P =
.001; Figure 1C). These results support the possibility that an MEK
inhibitor could overcome resistance to BRAF inhibition.
This study also showed that BRAF inhibitors could be safely
administered to patients with metastatic noncutaneous melanoma.
Most of the adverse events were grade 1 or simply manageable with
supportive care. There was one patient treated with dabrafenib and
trametinib who showed a grade 3 decreased cardiac ejection fraction
and stopped the treatment. This patient had arrhythmia and ischemic
heart disease before treatment, and medical professionals should
exercise caution when administering trametinib to patients who have
a history of cardiac problems.Marked heterogeneity of intrinsic and acquired resistance
mechanisms to BRAF inhibitors is known to be present in patients
with BRAF-mutant melanoma [12,14,30,31]. One of our patients
suspected to have primary resistance to BRAF inhibitors had
mutations in CDKN1B, ELMO1, and IKZF1. CDKN1B(p27)
regulates cell cycle and is also known as a tumor suppressor [32].
Trametinib, as an MEK1/2 inhibitor, decreases the expression of
Ki67 and increases the expression of CDKN1B [33]. A CDKN1B
mutation could be related to trametinib resistance or tumor
progression. A recent genomic study of esophageal cancer showed
that ELMO1 mutation increases invasiveness and is related with
tumorigenesis [34]. IKZF1 encodes the Ikaros transcription factor, a
crucial element for hematopoiesis, and IKZF1 mutation is related to
B-cell acute lymphoblastic leukemia [35]. Although the ELMO and
IKZF1 mutations were identified in our patient suspected to have
primary resistance to BRAF inhibitors, correlation with clinical
outcome is unknown.
Functional loss of NF1 has been described as a mechanism of
resistance to BRAF inhibitors [36]. We observed that tumors with the
NF1 mutation had an inferior response compared with NF1
wild-type melanoma. The patient who harbored EGFR and PTEN
mutations showed a relatively short response of 7.7 months. EGFR
expression could be related to vemurafenib resistance [37], and PTEN
loss induces the failure of BRAF inhibitors through intrinsic resistance
[38,39]. MAP2K2 is a downstream effector of the mitogen-activated
protein kinase pathway and plays a role in resistance to BRAF
inhibitors [14]. The MAP2K2 mutation was identified in two
samples, but the response in those patients was durable.
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Translational Oncology Vol. 9, No. 6, 2016 BRAF inhibitors in noncutaneous melanoma Kim et al. 563Although the sample size for this study was too small to definitely
confirm the efficacy of BRAF inhibitors and resistance mechanism in
metastatic noncutaneousmelanoma, the treatment outcome parameters
in this small cohort were comparable (ORR of 80% and a median PFS
of 7.3 months in noncutaneous melanoma) to those reported in large
phase III cutaneousmelanoma trials.Hence, BRAF inhibitors should be
strongly considered as upfront treatment for metastatic melanoma with
confirmed BRAFmutation regardless of site of origin (acral, mucosal, or
cutaneous). Further investigation into genetic alterations is needed to
understand and overcome the underlying mechanisms of resistance to
BRAF inhibitors.
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